NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) resulting from allegations that ACADIA may have issued materially misleading business information to the investing public.
On April 9, 2018, CNN issued a report that raised questions about whether ACADIA’s Nuplazid treatment played a role in the deaths of sick and elderly patients. On this news, shares of ACADIA fell $5.03 or over 23% to close at $16.50 per share on April 9, 2018.
Then, on July 9, 2018, The Southern Investigative Reporting Foundation issued a report stating that ACADIA’s “pursuit of regulatory approval is best described as ‘loophole-centric.’” On this news, shares of ACADIA fell $1.21 or over 6.7% to close at $16.63 per share on July 9, 2018.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by ACADIA investors. If you purchased shares of ACADIA please visit the firm’s website at http://www.rosenlegal.com/cases-1376.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.
Attorney Advertising. Prior results do not guarantee a similar outcome.